glucagon-like peptide-1

glucagon-like peptide-1 is an incretin hormone primarily secreted by enteroendocrine L-cells in the distal ileum and colon following nutrient ingestion. It plays a central role in glucose homeostasis by enhancing glucose-dependent insulin secretion from pancreatic beta cells. Its potent effects on appetite regulation and gastric emptying have made it a major target for the development of antidiabetic medication and anti-obesity medication.

Structure and production

The bioactive form is derived from the proglucagon gene, which is expressed in pancreatic alpha cells, enteroendocrine L-cells, and specific neurons within the nucleus tractus solitarius of the brainstem. Post-translational processing by prohormone convertase 1/3 in intestinal cells yields the major circulating forms, GLP-1(7-36) amide and GLP-1(7-37)]. These peptides are rapidly degraded by the dipeptidyl peptidase-4 enzyme, resulting in a very short plasma half-life of approximately two minutes. The amino acid sequence is highly conserved across mammals, underscoring its critical physiological role.

Physiological functions

Its primary physiological actions are mediated through the widely expressed GLP-1 receptor. In the endocrine pancreas, it potentiates glucose-stimulated insulin secretion while suppressing glucagon release from pancreatic alpha cells. Within the gastrointestinal tract, it inhibits gastric acid secretion and slows gastric emptying, contributing to increased satiety. In the central nervous system, it acts on hypothalamic and brainstem receptors to promote fullness and reduce food intake. Additional effects include potential modulation of cardiovascular function and neuroprotection.

Therapeutic applications

The discovery of its insulinotropic properties led to the development of GLP-1 receptor agonists, a cornerstone class in modern type 2 diabetes management. Notable agents include exenatide, liraglutide, semaglutide, and dulaglutide, which are engineered to resist DPP-4 degradation. These drugs improve glycemic control, often promote weight loss, and have demonstrated cardiovascular benefits in outcomes trials like LEADER and SUSTAIN-6. Furthermore, higher-dose formulations such as liraglutide and semaglutide are approved by the U.S. Food and Drug Administration and the European Medicines Agency for chronic weight management.

Receptor and mechanism of action

The GLP-1 receptor is a G protein-coupled receptor belonging to the class B secretin receptor family. It is coupled primarily to Gs alpha subunit, leading to activation of adenylyl cyclase and increased intracellular cyclic AMP levels. This cascade activates protein kinase A and Epac2, which ultimately facilitate insulin exocytosis. Receptor signaling also involves beta-arrestin recruitment and can activate secondary pathways like phospholipase C. The receptor is distributed in pancreatic islets, lungs, heart, kidneys, gastrointestinal tract, and multiple regions of the central nervous system, accounting for the hormone's pleiotropic effects.

Research and clinical development

Ongoing research explores its potential in neurodegenerative diseases, with clinical trials investigating semaglutide in Alzheimer's disease and Parkinson's disease. Cardiovascular outcome studies, including REWIND and PIONEER 6, continue to assess long-term safety and efficacy. Novel delivery methods, such as oral semaglutide approved by the FDA, represent significant advances in patient convenience. Future directions include the development of dual agonists and triple agonists that co-activate the GIP receptor and glucagon receptor, and investigating its role in non-alcoholic steatohepatitis and peripheral artery disease.

Category:Peptide hormones Category:Diabetes Category:Gastrointestinal hormones